Intelence
Intelence is the brand name for etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It is prescribed as part of combination antiretroviral therapy for treatment-experienced adults and certain pediatric patients, particularly those with resistance or intolerance to other NNRTIs. Intelence was approved by the U.S. FDA in 2008 and is marketed by Janssen.
Mechanism of action: Etravirine binds to an allosteric site on the HIV-1 reverse transcriptase enzyme, inhibiting
Medical uses: Intelence is indicated for treatment-experienced individuals with HIV-1 infection, in combination with other antiretroviral
Administration and dosage: The usual dose is 200 mg taken orally twice daily with meals to optimize
Safety and precautions: Common adverse effects include rash, nausea, diarrhea, fatigue, and headache. Serious rash, hypersensitivity